Windtree Therapeutics announces istaroxime Phase 2 study called SEISMiC B

Windtree Therapeutics (WINT) announced that the istaroxime early cardiogenic shock Phase 2 study called SEISMiC B is published in the Journal of Heart and Lung Transplantation and is available on the journal website. The publication is entitled “Safety and Efficacy Intravenous Istaroxime up to 60 hours for Patients with Pre-Cardiogenic Shock.” Patients with this condition have poor cardiac function, low blood pressure and need rapid treatment. The article notes in the SEISMiC B study that istaroxime significantly increased blood pressure over the first six hours of treatment and persisted for 60 hours. Patients also had significantly improved cardiac output, decreased pulmonary capillary wedge pressure, no increase in heart rate, no increase in clinically significant arrythmias and preserved renal function, a very unique profile of potential beneficial effects for this patient population.